Gland Pharma

When is the next results date for Gland Pharma?

No Upcoming Board Meetings

Has Gland Pharma declared dividend?

Yes, Gland Pharma has declared a dividend of 2000% (₹20 per share) with an ex-date of August 16, 2024. While the dividend yield is 1.23%, total returns have varied, showing negative performance in the short term but a strong positive return of 76.32% over the last two years.

Gland Pharma Ltd has declared a dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 2000%<BR>- Amount per share: 20 per share<BR>- Ex-date: 16 Aug 24<BR><BR>Dividend Yield: 1.23%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -9.24%, the dividend return was 0%, resulting in a total return of -9.24%.<BR><BR>Over the past year, the price return was -10.71%, with a dividend return of 1.06%, leading to a total return of -9.65%.<BR><BR>For the 2-year period, the price return was 74.37%, the dividend return was 1.95%, resulting in a total return of 76.32%.<BR><BR>In the last 3 years, the price return was -42.39%, the dividend return was 0.77%, leading to a total return of -41.62%.<BR><BR>Over the past 4 years, the price return was -47.67%, with a dividend return of 0.62%, resulting in a total return of -47.05%.<BR><BR>In the last 5 years, the price return was 0%, the dividend return was 0%, leading to a total return of 0.0%.<BR><BR>Overall, Gland Pharma has declared a significant dividend, but the total returns over various periods show a mixed performance, with negative returns in the shorter terms and a strong positive return over the 2-year period.

Who are the peers of the Gland Pharma?

Gland Pharma's peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, J B Chemicals, Pfizer, Emcure Pharma, and Wockhardt. Gland Pharma has a good management risk rating but shows below-average growth and a 1-year return of -11.87%, significantly lower than Wockhardt's 174.76%.

Peers: Gland Pharma's peers include Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, J B Chemicals &, Pfizer, Emcure Pharma, and Wockhardt.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Cipla, Dr Reddy's Labs, and the rest. Good management risk is found at Divi's Lab., Torrent Pharma, Gland Pharma, J B Chemicals &, Pfizer, Emcure Pharma, and Wockhardt. Below Average growth is noted at Divi's Lab., Torrent Pharma, Gland Pharma, Pfizer, and Emcure Pharma, while Excellent growth is seen at Sun Pharma.Inds., Cipla, and Dr Reddy's Labs. Average growth is present at J B Chemicals &, and the rest. Excellent capital structure is held by Sun Pharma.Inds., Divi's Lab., Cipla, Dr Reddy's Labs, Gland Pharma, J B Chemicals &, Pfizer, while Good capital structure is noted at Torrent Pharma and Emcure Pharma, and Below Average capital structure is found at Wockhardt.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Wockhardt at 174.76%, while Gland Pharma has the lowest at -11.87%. Gland Pharma's return is significantly lower than the highest peer. Additionally, the six-month return is negative for Gland Pharma, Emcure Pharma, and Wockhardt.

Who are in the management team of Gland Pharma?

As of March 2023, Gland Pharma's management team includes Chairman Yiu Kwan Stanley Lau, Managing Director & CEO Srinivas Sadu, and several non-executive and independent directors, totaling nine key members.

As of March 2023, the management team of Gland Pharma includes the following individuals:<BR><BR>1. Yiu Kwan Stanley Lau - Chairman & Independent Director<BR>2. Srinivas Sadu - Managing Director & CEO<BR>3. Qiyu Chen - Non-Executive & Non-Independent Director<BR>4. Udo Johannes Vetter - Non-Executive & Non-Independent Director<BR>5. C S N Murthy - Independent Director<BR>6. Essaji Goolam Vahanvati - Independent Director<BR>7. Naina Lal Kidwai - Independent Director<BR>8. Jia Ai (Allen) Zhang - Non-Executive & Non-Independent Director<BR>9. Yao Fang - Non-Executive & Non-Independent Director<BR><BR>This team comprises a mix of executive and non-executive directors, with several independent directors contributing to the governance of the company.

What does Gland Pharma do?

Gland Pharma Ltd is a large-cap pharmaceutical company, incorporated in 1978, with net sales of ₹14,249 Cr and a net profit of ₹1,865 Cr for the quarter ending March 2025. It has a market cap of ₹31,575 Cr and key metrics include a P/E ratio of 46.00 and a dividend yield of 1.05%.

Overview:<BR>Gland Pharma Ltd is a large-cap company operating in the Pharmaceuticals & Biotechnology industry.<BR><BR>History:<BR>Gland Pharma Limited was incorporated as 'Gland Pharma Private Limited' on March 20, 1978, and later renamed to 'Gland Pharma Limited' with a fresh certificate of incorporation issued on April 25, 1995. The most recent quarterly results report net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot:<BR>- Net Sales: 14,249 Cr (Quarterly Results - Mar 2025)<BR>- Net Profit: 1,865 Cr (Quarterly Results - Mar 2025)<BR>- Market Cap: INR 31,575 Cr (Large Cap)<BR><BR>Key Metrics:<BR>- P/E: 46.00<BR>- Industry P/E: 37<BR>- Dividend Yield: 1.05%<BR>- Debt Equity: -0.25<BR>- Return on Equity: 7.63%<BR>- Price to Book: 3.41<BR><BR>Contact Details:<BR>Registrar Address: Not available.

Who are the top shareholders of the Gland Pharma?

The top shareholders of Gland Pharma include Fosun Pharma Industrial Pte. Ltd. with 51.83%, mutual funds with 31.16%, and foreign institutional investors holding 6.9%. The largest public shareholder is Mirae Asset Large & Midcap Fund at 6.78%, while individual investors own 2.99%.

The top shareholders of Gland Pharma include Fosun Pharma Industrial Pte. Ltd, which holds the largest stake at 51.83%. Additionally, mutual funds collectively hold 31.16% of the shares, with 24 different schemes involved. Among foreign institutional investors (FIIs), there are 163 holding 6.9% of the company. The highest public shareholder is Mirae Asset Large & Midcap Fund, which owns 6.78%. Individual investors account for 2.99% of the holdings.

How big is Gland Pharma?

As of 24th July, Gland Pharma Ltd has a market capitalization of 32,804.00 Cr, with recent net sales of 5,616.50 Cr and a net profit of 698.52 Cr.

As of 24th July, Gland Pharma Ltd has a market capitalization of 32,804.00 Cr, categorizing it as a Large Cap company.<BR><BR>In the latest four quarters, Gland Pharma reported Net Sales of 5,616.50 Cr and a Net Profit of 698.52 Cr.<BR><BR>The latest annual period for the balance sheet is March 2024, with Shareholder's Funds amounting to 8,723.84 Cr and Total Assets of 10,610.81 Cr.

Is Gland Pharma overvalued or undervalued?

As of November 7, 2025, Gland Pharma is considered overvalued with a PE ratio of 38.88, an EV to EBITDA of 4.16, and a PEG ratio of 2.72, indicating it is more expensive compared to peers like Sun Pharma and Cipla, and has underperformed the Sensex recently.

As of 7 November 2025, Gland Pharma's valuation grade has moved from very expensive to expensive, indicating a shift in perception regarding its market worth. The company is currently considered overvalued. Key ratios include a PE ratio of 38.88, an EV to EBITDA of 4.16, and a Price to Book Value of 0.32, which suggest that while the company has a low book value relative to its market price, its earnings multiples are high compared to peers.<BR><BR>In comparison to its industry peers, Gland Pharma's PE ratio is higher than Sun Pharma's 35.17 and significantly higher than Cipla's attractive PE of 22.33. Additionally, the PEG ratio of 2.72 indicates that the stock may not be growing fast enough to justify its current price. Recent stock performance shows that Gland Pharma has underperformed the Sensex over the past week and month, which further supports the view that it is overvalued in the current market context.

How has been the historical performance of Gland Pharma?

Gland Pharma's historical performance shows fluctuating financial metrics, with net sales and profits declining from March 2024 to March 2025, despite an increase in total assets. The company experienced a significant recovery in net cash inflow, contrasting with previous outflows.

Answer:<BR>The historical performance of Gland Pharma shows a fluctuating trend in key financial metrics over the past six years.<BR><BR>Breakdown:<BR>Gland Pharma's net sales peaked at 5,664.72 Cr in March 2024 but slightly decreased to 5,616.50 Cr in March 2025. The total operating income followed a similar pattern, reaching 5,664.72 Cr in March 2024 and then declining to 5,616.50 Cr in March 2025. The company's operating profit (PBDIT) also saw a decrease from 1,503.31 Cr in March 2024 to 1,482.53 Cr in March 2025. Profit before tax was 1,062.66 Cr in March 2025, down from 1,132.54 Cr in March 2024, while profit after tax decreased to 698.53 Cr from 772.46 Cr in the previous year. The earnings per share (EPS) fell from 46.90 in March 2024 to 42.39 in March 2025. On the balance sheet, total assets increased to 11,172.85 Cr in March 2025 from 10,610.81 Cr in March 2024, with total liabilities also rising to 11,172.85 Cr. The cash flow from operating activities decreased to 914 Cr in March 2025 from 996 Cr in March 2024, while the net cash inflow for March 2025 was 2,199 Cr, a significant recovery from the outflow of 1,551 Cr in March 2024. Overall, Gland Pharma's financial performance reflects a mix of growth in assets and fluctuations in profitability over the years.

Is Gland Pharma technically bullish or bearish?

As of December 4, 2025, Gland Pharma's technical trend is mildly bearish, supported by bearish MACD readings, Bollinger Bands, and underperformance against the Sensex, despite some mixed signals from KST and daily moving averages.

As of 4 December 2025, the technical trend for Gland Pharma has changed from sideways to mildly bearish. The current stance is mildly bearish, driven by the weekly and monthly MACD readings, both indicating a bearish sentiment. The Bollinger Bands also reflect a bearish trend on both time frames. The KST shows a mixed signal with a bullish monthly reading but a mildly bearish weekly signal, while the Dow Theory and OBV both confirm a mildly bearish outlook. The daily moving averages are mildly bullish, but this is overshadowed by the overall bearish indicators. The stock has underperformed against the Sensex over multiple periods, further supporting the bearish stance.

Are Gland Pharma Ltd latest results good or bad?

Gland Pharma Ltd's latest Q3 FY26 results show strong revenue growth of 22.49% and a net profit increase of 36.30%, but declining operating margins and return on equity raise concerns about long-term sustainability. Investors should weigh these mixed signals when assessing the company's performance.

Gland Pharma Ltd's latest results for Q3 FY26 show a mixed performance. On the positive side, the company reported a net profit of ₹279.06 crores, which is a significant increase of 36.30% year-on-year. Revenue also saw a robust growth of 22.49% year-on-year, reaching ₹1,695.36 crores, marking the highest quarterly revenue in its recent history.<BR><BR>However, there are some concerning aspects as well. The operating margin decreased to 19.07%, down 201 basis points from the previous year, indicating pressure on profitability despite the revenue growth. Additionally, the return on equity has declined to 8.27%, which is below historical averages and raises concerns about the company's capital efficiency.<BR><BR>Overall, while the revenue and profit figures are encouraging, the decline in margins and return metrics suggests that Gland Pharma is facing challenges that could impact its long-term sustainability. Investors might want to consider these factors carefully when evaluating the company's performance.

Which are the latest news on Gland Pharma?

Should I buy, sell or hold Gland Pharma Ltd?

Why is Gland Pharma Ltd falling/rising?

As of 13-Mar, Gland Pharma Ltd's stock price is declining, currently at 1,624.00, with a total drop of -3.71% over the last three days. The stock is underperforming in the short term and has a concerning long-term outlook despite some positive factors.

As of 13-Mar, Gland Pharma Ltd's stock price is falling, currently at 1,624.00, reflecting a decrease of 32.45 (-1.96%). This decline is part of a broader trend, as the stock has been losing value for the last three days, resulting in a total drop of -3.71% during this period. Additionally, the stock is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a bearish trend.<BR><BR>In terms of performance relative to the market, Gland Pharma's returns over the past week and month are negative, at -2.70% and -8.75%, respectively, although it has outperformed the Sensex in the same periods. The stock's year-to-date performance shows a decline of -5.71%, while it has managed a positive return of +4.49% over the past year. However, the long-term outlook appears concerning, as the company has experienced poor growth in operating profit, with an annual rate of -1.16% over the last five years.<BR><BR>Despite some positive factors, such as high institutional holdings at 40.56% and strong quarterly results, the stock's expensive valuation, indicated by a Price to Book Value of 2.8 and a PEG ratio of 1.4, suggests that it is trading at a premium compared to its peers. This combination of factors contributes to the current downward pressure on Gland Pharma's stock price.

Why is Gland Pharma Ltd falling/rising?

As of 14-Mar, Gland Pharma Ltd's stock price is declining, currently at 1,624.00, down 1.96%. The stock has underperformed against the Sensex and shows bearish trends, with significant selling pressure and challenges in long-term growth despite recent positive quarterly results.

As of 14-Mar, Gland Pharma Ltd's stock price is falling, currently at 1,624.00, which represents a decrease of 32.45 or 1.96%. The stock has been on a downward trend, having lost value for the last three consecutive days, with a total decline of 3.71% during this period. Additionally, the stock has underperformed relative to the benchmark Sensex, with a 1-week return of -2.70% compared to the Sensex's -5.52%.<BR><BR>The stock's performance today aligns with the sector, but it has touched an intraday low of Rs 1,602.1, indicating significant selling pressure. Gland Pharma is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, which typically suggests a bearish trend. Despite a notable increase in delivery volume, which rose by 1006.74% on March 12, the overall sentiment appears negative.<BR><BR>Furthermore, the company faces challenges regarding long-term growth, as indicated by an annual operating profit decline of -1.16% over the past five years. Although the company reported positive quarterly results with the highest net sales and profit before tax growth, its return on equity (ROE) of 8.3 and a price-to-book value of 2.8 suggest that the stock is trading at a premium compared to its peers. This expensive valuation, combined with the relatively modest profit growth of 22.8% over the past year, contributes to a negative outlook, reflected in the stock's current decline.

Why is Gland Pharma Ltd falling/rising?

As of 15-Mar, Gland Pharma Ltd's stock price is declining, currently at 1,624.00, with a total drop of 3.71% over the last three days. The stock is underperforming against the Sensex and has weak long-term growth prospects, leading to cautious investor sentiment despite increased delivery volume.

As of 15-Mar, Gland Pharma Ltd's stock price is falling, currently at 1,624.00, reflecting a decrease of 32.45 (-1.96%). The stock has been on a downward trend, having lost value for the last three consecutive days, resulting in a total decline of 3.71% during this period. Additionally, the stock is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a bearish sentiment.<BR><BR>In terms of performance relative to the market, Gland Pharma's stock has underperformed compared to the Sensex over various periods, including a 1-week decline of 2.70% against the Sensex's 5.52% drop and a 1-month decline of 8.75% compared to the Sensex's 9.76% decline. Despite a positive annual return of 4.49%, the stock's long-term growth prospects appear weak, with an operating profit growth rate of -1.16% over the last five years.<BR><BR>Investor sentiment may also be affected by the stock's valuation, which is considered expensive with a Price to Book Value of 2.8, higher than its peers. This, combined with a relatively low return on equity (ROE) of 8.3, suggests that investors may be cautious. Although there has been a significant increase in delivery volume, indicating rising investor participation, the overall trend and performance metrics suggest that the stock is currently facing downward pressure.